Drugs / Tagatose
Tagatose
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00961662 | Feb 2008 → Aug 2010 | type 2 diabetes mellitus | Robert Lodder | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00955747 | Apr 2007 → Oct 2010 | type 2 diabetes mellitus | Robert Lodder | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tagatose | “Naturlose™ (Tagatose)” NCT00961662 ↗ |
| Known as | D-Tagatose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00961662 ↗ |
| Known as | Naturlose | ChEMBL registry synonym — accepted as the source's own label CHEMBL1236183 ↗ |
| Modality | Small molecule | — CHEMBL1236183 ↗ |
| Route | Oral | “given orally” NCT00961662 ↗ |